Vincent S. LoPriore, Executive Chairman and Director of Hepion Pharmaceuticals, Inc., filed a Form 4 on October 27, 2026, disclosing the acquisition of stock options on October 23, 2026.

Key Highlights

  • Reporting person: Vincent S. LoPriore, identified in the filing as Executive Chairman and Director of Hepion Pharmaceuticals, Inc.
  • Options acquired: 1,530,000 stock options received on October 23, 2026, with a transaction code of A (acquired).
  • Exercise price: $0.14 per share, as stated in the filing.
  • Expiration date: October 23, 2036, according to the filing.
  • Vesting schedule: 127,500 options vest in equal amounts monthly over 12 months from the date of grant, per the filing's footnote.
  • Post-transaction holdings: LoPriore beneficially owned 2,875,500 derivative securities following the reported transaction, as disclosed in the filing.
  • Price of derivative security: $0, as reported in Table II.

LoPriore's October 2026 Stock Option Grant at Hepion Pharmaceuticals

According to the Form 4 filing submitted to the SEC on October 27, 2026, Vincent S. LoPriore, serving as Executive Chairman and Director of Hepion Pharmaceuticals, Inc. (OTC:HEPA), received a grant of 1,530,000 stock options on October 23, 2026. The options carry an exercise price of $0.14 and are exercisable into shares of common stock. The options are set to expire on October 23, 2036, giving them a ten-year term from the grant date.

The filing's explanation of responses notes that 127,500 options vest in equal amounts monthly over 12 months from the date of grant. The price of the derivative security is listed as $0. Following this transaction, the filing discloses that LoPriore beneficially owned 2,875,500 derivative securities on a direct basis. No transactions were reported in Table I, which covers non-derivative securities. The filing was signed by Vincent LoPriore on October 27, 2026, and indicates it was filed by one reporting person.

What Was Disclosed

The filing discloses the acquisition of 1,530,000 stock options by Hepion Pharmaceuticals' Executive Chairman Vincent S. LoPriore on October 23, 2026, at an exercise price of $0.14, expiring October 23, 2036, with monthly vesting of 127,500 options over 12 months.